Hutchison China MediTech logo

HCM - Hutchison China MediTech Share Price

357p 13.0  3.8%

Last Trade - 04/06/20

Sector
Healthcare
Size
Mid Cap
Market Cap £2.47bn
Enterprise Value £2.34bn
Revenue £162.7m
Position in Universe 238th / 1817
Bullish
Bearish
Unlock HCM Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Hutchison China MediTech Limited revenues decreased 4% to $204.9M. Net loss increased 42% to $106M. Revenues reflect Is Operating - Drug R&D segment decrease of 61% to $16M, Is Operating - Consumer Health Hong kong segment decrease of 19% to $22.8M, Is Operating - Consumer Health PRC segment decrease of 3% to $11.6M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

HCM Revenue Unlock HCM Revenue

Net Income

HCM Net Income Unlock HCM Revenue

Normalised EPS

HCM Normalised EPS Unlock HCM Revenue

PE Ratio Range

HCM PE Ratio Range Unlock HCM Revenue

Dividend Yield Range

HCM Dividend Yield Range Unlock HCM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HCM EPS Forecasts Unlock HCM Revenue
Profile Summary

Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated December 18, 2000
Public Since May 19, 2006
No. of Shareholders: n/a
No. of Employees: 853
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Aim All Share , FTSE Aim 100 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 690,574,765
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HCM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for HCM
Upcoming Events for HCM
Thursday 4th June, 2020
Hutchison China MediTech Ltd at Jefferies Healthcare Conference (Virtual)
Frequently Asked Questions for Hutchison China MediTech
What is the Hutchison China MediTech share price?

As of 04/06/20, shares in Hutchison China MediTech are trading at 357p, giving the company a market capitalisation of £2.47bn. This share price information is delayed by 15 minutes.

How has the Hutchison China MediTech share price performed this year?

Shares in Hutchison China MediTech are currently trading at 357p and the price has moved by -12.93% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Hutchison China MediTech price has moved by -2.11% over the past year.

What are the analyst and broker recommendations for Hutchison China MediTech?

Of the analysts with advisory recommendations for Hutchison China MediTech, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Hutchison China MediTech is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Hutchison China MediTech next release its financial results?

Hutchison China MediTech is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Hutchison China MediTech dividend yield?

Hutchison China MediTech does not currently pay a dividend.

Does Hutchison China MediTech pay a dividend?

Hutchison China MediTech does not currently pay a dividend.

When does Hutchison China MediTech next pay dividends?

Hutchison China MediTech does not currently pay a dividend.

How do I buy Hutchison China MediTech shares?

To buy shares in Hutchison China MediTech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Hutchison China MediTech?

Shares in Hutchison China MediTech are currently trading at 357p, giving the company a market capitalisation of £2.47bn.

Where are Hutchison China MediTech shares listed? Where are Hutchison China MediTech shares listed?

Here are the trading details for Hutchison China MediTech:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: HCM
What kind of share is Hutchison China MediTech?

Based on an overall assessment of its quality, value and momentum, Hutchison China MediTech is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Hutchison China MediTech share price forecast 2020?

Shares in Hutchison China MediTech are currently priced at 357p. At that level they are trading at 31.92% discount to the analyst consensus target price of 524.38.

Analysts covering Hutchison China MediTech currently have a consensus Earnings Per Share (EPS) forecast of -0.34 for the next financial year.

How can I tell whether the Hutchison China MediTech share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hutchison China MediTech. Over the past six months, the relative strength of its shares against the market has been 12.89%. At the current price of 357p, shares in Hutchison China MediTech are trading at 2.41% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Hutchison China MediTech PE Ratio?

We were not able to find PE ratio data for Hutchison China MediTech.

Who are the key directors of Hutchison China MediTech?

Hutchison China MediTech's management team is headed by:

Christian Hogg - CEO
Simon To - CHM
Edith Shih - SEC
Dan Eldar - NED
Paul Carter - NID
Karen Ferrante - NID
Chig Fung Cheng - CFO
Weiguo Su - CSO
Shu Kam Mok - NID
Graeme Jack - NID
Mark Lee - SVF
May Wang - SVP
Zhenping Wu - SVP
Who are the major shareholders of Hutchison China MediTech?

Here are the top five shareholders of Hutchison China MediTech based on the size of their shareholding:

Hutchison Healthcare Holdings Ltd. Holding Company
Percentage owned: 48.15% (332.5m shares)
Mitsui & Co Ltd Corporation
Percentage owned: 2.34% (16.1m shares)
M & G Investment Management Ltd. Investment Advisor
Percentage owned: 1.58% (10.9m shares)
Hogg (Christian) Individual Investor
Percentage owned: 1.58% (10.9m shares)
FIL Investment Management (Hong Kong) Limited Investment Advisor
Percentage owned: 1.33% (9.21m shares)
Similar to HCM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.